617MO Repurposing metformin as an anticancer drug: Preliminary results of randomized controlled trial in advanced prostate cancer (MANSMED)

      There is growing evidence of antineoplastic properties of metformin (MET) in prostate cancer (PCa). Many observational studies suggested that using MET was associated with improvement in overall survival in PCa patients. MET was reported to be associated with reduction of risk of development of castration-resistant state (CRPC). In addition, when MET was combined to ADT or biclutamide, it augmented the antiproliferative effect of these drugs.
      To read this article in full you will need to make a payment
      Subscribe to Annals of Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect